Cardiovascular biotech Celladon revives IPO filing, removes original terms

By Renaissance Capital,

Shutterstock photo

Celladon, which is developing novel therapies for the treatment of heart disease, revived its IPO by filing an amended S-1 with the SEC on Wednesday. The company had previously launched a deal to sell 5 million shares at $14 to $16 per share but postponed on November 13. The company's updated filing removed the original IPO terms. The San Diego, CA-based company, which was founded in 2000, plans to list on the NASDAQ under the symbol CLDN. Barclays is the sole bookrunner on the deal. 

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: CLDN

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by